Independent Director's Annual Work Report of Aerospace Intelligent Manufacturing Technology Co., Ltd. (Zou Huawai)
Dear shareholders and shareholder representatives:
As an independent director of Aerospace Intelligent Manufacturing Technology Co., Ltd. (hereinafter referred to as "the Company"), I have strictly adhered to the provisions and requirements of the Company Law, Securities Law, Management Measures for Independent Directors of Listed Companies, Self-Regulatory Guidelines No. 2 for the Standardized Operation of GEM Listed Companies, the Articles of Association, and the Work Rules for Independent Directors during the year 2025. I have attended relevant meetings of the Company diligently, independently, and responsibly, keeping abreast of the Company's operational information, focusing on its development status, and carefully reviewing all proposals from the board of directors and its specialized committees. I have independently expressed opinions during the review of significant matters, fully exercising the role of independent directors in decision-making, supervision, and professional consultation, safeguarding the overall interests of the listed company and protecting the legitimate rights and interests of minority shareholders, while contributing suggestions for the Company's long-term development. Below is my report on the performance of my duties as an independent director for 2025:
I. Basic Information of the Independent Director
I, Zou Huawai, was born in November 1978, graduated with a doctoral degree, and am a professor and a member of the Communist Party of China. I currently serve as a professor at Sichuan University, director of a key laboratory of the Ministry of Education, and independent director of Aerospace Intelligent Manufacturing. After careful self-examination, I confirm that my tenure complies with the independence requirements stipulated in Article 6 of the Management Measures for Independent Directors of Listed Companies, and there are no circumstances affecting my independence.
II. Performance in 2025
(A) Meeting Participation
- In 2025, the Company held 8 board meetings, all of which I personally attended. I carefully reviewed all proposals submitted to the board, prudently exercised my voting rights, and safeguarded the overall interests of the Company and the rights of minority shareholders. The Company also held 5 shareholder meetings, all of which I personally attended.
- Prior to the meetings, with the cooperation of the Company's board office, I timely obtained the necessary materials and information for the meeting discussions, leveraging my professional expertise to review matters related to fundraising management and compliance of related party transactions. During the meetings, I carefully reviewed each proposal based on an independent judgment stance, actively participated in discussions, and made reasonable suggestions, contributing positively to scientific decision-making.
- I believe that the convening and holding of the board and shareholder meetings in 2025 complied with legal procedures, and all significant operational decisions and other major matters followed the relevant procedures, being legal and effective. I voted in favor of all board proposals, with no objections or abstentions.
(B) Special Meetings of Independent Directors
In 2025, the Company held 3 special meetings for independent directors. On January 27, 2025, the Company convened the second special meeting of the fifth board of independent directors, where I conducted a pre-review of related party transactions formed through public bidding by the Company's subsidiary Chengdu Aerospace Molding Co., Ltd., agreeing to submit it for board review. On March 26, 2025, the third special meeting was held, where I pre-reviewed the Company's 2024 routine related party transactions and the expected routine related party transactions for 2025, as well as the proposed signing of a Financial Service Agreement with Aerospace Technology Finance Co., Ltd., agreeing to submit it for board review. On June 23, 2025, the fourth special meeting was held, where I pre-reviewed related party transactions formed through public bidding by the Company's subsidiary Lekai Chemical Materials Co., Ltd., agreeing to submit it for board review.